ENDURANCE Trail for Patients with Newly Diagnosed Symptomatic Multiple Myeloma
The purpose of this study is to compare the effects, good and/or bad, of a combination of carfilzomib, lenalidomide and dexamethasone with a combination of bortezomib, lenalidomide and dexamethasone in patients newly diagnosed with symptomatic multiple myeloma.
Contact: Katie Colbeck, 413-794-9875
December 03, 2013
Cancer - Multiple Myeloma
D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA
Patients with newly diagnosed multiple myeloma
Interventional (Clinical Trial), Randomized